- Home
- MAMA vs BMEA Comparison
MAMA vs BMEA Comparison
Compare MAMA & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAMA
- BMEA
- Stock Information
- Founded
- MAMA 2010
- BMEA 2017
- Country
- MAMA United States
- BMEA United States
- Employees
- MAMA N/A
- BMEA N/A
- Industry
- MAMA Specialty Foods
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- MAMA Consumer Staples
- BMEA Health Care
- Exchange
- MAMA Nasdaq
- BMEA Nasdaq
- Market Cap
- MAMA 323.1M
- BMEA 65.8M
- IPO Year
- MAMA N/A
- BMEA 2021
- Fundamental
- Price
- MAMA $9.25
- BMEA $1.86
- Analyst Decision
- MAMA Strong Buy
- BMEA Strong Buy
- Analyst Count
- MAMA 3
- BMEA 10
- Target Price
- MAMA $10.33
- BMEA $21.00
- AVG Volume (30 Days)
- MAMA 241.7K
- BMEA 1.5M
- Earning Date
- MAMA 09-09-2025
- BMEA 07-30-2025
- Dividend Yield
- MAMA N/A
- BMEA N/A
- EPS Growth
- MAMA N/A
- BMEA N/A
- EPS
- MAMA 0.11
- BMEA N/A
- Revenue
- MAMA $128,745,000.00
- BMEA N/A
- Revenue This Year
- MAMA $17.24
- BMEA N/A
- Revenue Next Year
- MAMA $9.95
- BMEA N/A
- P/E Ratio
- MAMA $83.94
- BMEA N/A
- Revenue Growth
- MAMA 17.04
- BMEA N/A
- 52 Week Low
- MAMA $5.50
- BMEA $1.29
- 52 Week High
- MAMA $9.98
- BMEA $13.07
- Technical
- Relative Strength Index (RSI)
- MAMA 68.62
- BMEA 48.52
- Support Level
- MAMA $8.81
- BMEA $1.77
- Resistance Level
- MAMA $9.10
- BMEA $1.97
- Average True Range (ATR)
- MAMA 0.38
- BMEA 0.13
- MACD
- MAMA 0.04
- BMEA 0.01
- Stochastic Oscillator
- MAMA 97.08
- BMEA 66.67
About MAMA Mama's Creations Inc.
Mama's Creations Inc is a marketer and manufacturer of fresh deli-prepared foods, found in grocery, mass, club, and convenience stores nationally. The company's broad product portfolio, born from a rich history in Italian foods, now consists of a variety of high-quality, fresh, clean, and easy-to-prepare foods to address the needs of both consumers and retailers. The brand of the company includes Mama's Creations, Mama's Mancini's, The Olive Branch, Creative Salads, and others.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.